MY153263A - Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels - Google Patents

Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels

Info

Publication number: MY153263A
Authority: MY; Malaysia
Prior art keywords: treatment; heterocyclic compounds; diseases related; compounds suitable; lipid levels
Prior art date: 2006-08-15

Application number

MYPI20090434A

Other languages

English (en)

Inventor

Dales Natalie

Zhang Zaihui

Fonarev Julia

Fu Jianmin

Kamboj Rajender

Kodumuru Vishnumurthy

Liu Shifeng

Pokrovskaia Natalia

Raina Vandna

Sun Shaoyi

Original Assignee

Novartis Ag

Xenon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-15

Filing date

2007-08-13

Publication date

2015-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39864516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY153263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-13 Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag

2015-01-29 Publication of MY153263A publication Critical patent/MY153263A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Virology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)

MYPI20090434A 2006-08-15 2007-08-13 Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels MY153263A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US82245906P	2006-08-15	2006-08-15

Publications (1)

Publication Number	Publication Date
MY153263A true MY153263A (en)	2015-01-29

Family

ID=39864516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MYPI20090434A MY153263A (en)	2006-08-15	2007-08-13	Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels

Country Status (27)

Country	Link
US (2)	US8063084B2 (es)
EP (1)	EP2054408B1 (es)
JP (1)	JP4972690B2 (es)
KR (4)	KR20090040385A (es)
CN (1)	CN101535303B (es)
AR (1)	AR062360A1 (es)
AU (1)	AU2007351498B2 (es)
BR (1)	BRPI0716407A2 (es)
CA (1)	CA2660201C (es)
CL (1)	CL2007002348A1 (es)
CO (1)	CO6241156A2 (es)
CR (1)	CR10566A (es)
ES (1)	ES2597453T3 (es)
GT (1)	GT200900027A (es)
IL (1)	IL196562A0 (es)
MA (1)	MA30655B1 (es)
MX (1)	MX2009001634A (es)
MY (1)	MY153263A (es)
NO (1)	NO20091083L (es)
NZ (2)	NZ574222A (es)
PE (3)	PE20081316A1 (es)
RU (1)	RU2009109147A (es)
TN (1)	TN2009000045A1 (es)
TW (1)	TWI404718B (es)
UA (1)	UA96766C2 (es)
WO (1)	WO2008127349A2 (es)
ZA (1)	ZA200900263B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20090040385A (ko)	2006-08-15	2009-04-23	노파르티스 아게	증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물
EA200900820A1 (ru)	2006-12-20	2010-02-26	Новартис Аг	2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд)
BRPI0815979A2 (pt)	2007-08-28	2017-06-13	Irm Llc	compostos e composições com inibidores de quinase, bem como uso dos mesmos
EA022797B1 (ru) *	2008-02-20	2016-03-31	Новартис Аг	ТРИАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ СТЕАРОИЛ-CoA-ДЕСАТУРАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ, И ИХ ПРИМЕНЕНИЕ
AU2013200845B2 (en) *	2008-02-20	2015-01-29	Xenon Pharmaceuticals Inc.	Heterocyclic inhibitors of stearoyl-CoA desaturase
US8445505B2 (en)	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
UY31929A (es)	2008-06-25	2010-01-05	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
EP2398809B1 (en)	2009-02-17	2015-07-08	Merck Canada Inc.	Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8383643B2 (en)	2009-07-28	2013-02-26	Merck Canada Inc.	Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
PH12012500648A1 (en) *	2009-10-01	2012-11-12	Novartis Ag	Pyrazole derivatives which modulate stearoyl-coa desaturase
US9296719B2 (en) *	2011-07-08	2016-03-29	Indiana University Research And Technology Corporation	Compositions and methods for the treatment of norovirus infection
BR112014008590A2 (pt)	2011-10-15	2017-10-24	Genentech Inc	métodos de uso de antagonistas de scd1
US9505728B2 (en)	2012-03-09	2016-11-29	Inception 2, Inc.	Triazolone compounds and uses thereof
EP2858501A4 (en) *	2012-05-22	2015-12-09	Merck Sharp & Dohme	TRKA KINASE INHIBITORS, COMPOSITIONS AND METHOD THEREFOR
BR112014029365A2 (pt)	2012-05-22	2017-06-27	Hoffmann La Roche	inibidores seletivos de células indiferenciadas
CN104918922B (zh)	2012-12-20	2017-04-26	因森普深2公司	三唑酮化合物及其用途
WO2015035059A1 (en)	2013-09-06	2015-03-12	Inception 2, Inc.	Triazolone compounds and uses thereof
SG11201608710TA (en) *	2014-04-28	2016-11-29	Jiangsu Kanion Parmaceutical Co Ltd	Anti-enterovirus 71 thiadiazolidine derivative
CN107427527B (zh)	2015-03-31	2021-01-26	英安塔制药有限公司	作为fxr/tgr5激动剂的胆汁酸衍生物及其使用方法
WO2017189651A1 (en)	2016-04-26	2017-11-02	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en)	2016-04-26	2017-11-02	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189652A1 (en)	2016-04-26	2017-11-02	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en)	2016-05-18	2018-12-04	Enanta Pharmaceuticals, Inc.	Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201152A1 (en)	2016-05-18	2017-11-23	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en)	2016-05-18	2017-11-23	Enanta Pharmaceuticals, Inc.	lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
MX2019003790A (es) *	2016-10-04	2019-09-26	Enanta Pharm Inc	Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
CN110099898B (zh)	2016-10-24	2023-07-25	优曼尼蒂治疗公司	化合物及其用途
WO2018081285A1 (en)	2016-10-26	2018-05-03	Enanta Pharmaceuticals, Inc.	Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN110392833A (zh)	2017-01-06	2019-10-29	优曼尼蒂治疗公司	治疗神经病症的方法
WO2019084157A1 (en)	2017-10-24	2019-05-02	Yumanity Therapeutics, Inc.	COMPOUNDS AND USES THEREOF
WO2019118571A1 (en)	2017-12-12	2019-06-20	Enanta Pharmaceuticals, Inc.	Isoxazole analogs as fxr agonists and methods of use thereof
WO2019160813A1 (en)	2018-02-14	2019-08-22	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as fxr agonists and methods of use thereof
CA3094527A1 (en)	2018-03-23	2019-09-26	Yumanity Therapeutics, Inc.	Compounds and uses thereof
SG11202108079RA (en)	2019-01-24	2021-08-30	Yumanity Therapeutics Inc	Compounds and uses thereof
US11555032B2 (en)	2019-05-13	2023-01-17	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as FXR agonists and methods of use thereof
CN111961034A (zh) *	2019-05-20	2020-11-20	浙江同源康医药股份有限公司	用作ret激酶抑制剂的化合物及其应用
CN115286616A (zh) *	2022-07-27	2022-11-04	北京师范大学	结合sigma-2受体的四氢异喹啉和异吲哚啉类化合物、其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1245971B (de)	1962-05-30	1967-08-03	Ciba Aktiengesellschaft, Basel (Schweiz)	Verfahren zur Herstellung von neuen Tetrahydro-imidazolen
CH455806A (de) *	1963-08-30	1968-05-15	Ciba Geigy	Verfahren zur Herstellung neuer Imidazole
CH463517A (de) *	1964-04-24	1968-10-15	Ciba Geigy	Verfahren zur Herstellung neuer Diazacycloalkanverbindungen
US4058617A (en) *	1972-10-04	1977-11-15	Ciba-Geigy Corporation	Imidazoles and pharmaceutical composition
CH590267A5 (es) *	1972-10-04	1977-07-29	Ciba Geigy Ag
IL44282A (en)	1974-02-25	1979-01-31	Ciba Geigy Ag	1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
US4116969A (en)	1976-06-01	1978-09-26	Velsicol Chemical Company	1-thiazolyl-5-hydroxyimidazolidinones
US4086240A (en) *	1976-06-01	1978-04-25	Velsicol Chemical Corporation	1-Thiazolyl-5-phenoxy and phenylthioalkanoyloxyimidazolidinones
NZ184081A (en) *	1976-06-01	1980-10-08	Velsicol Chemical Corp	1-thiazol-2-yl-1 3-imidazolidn-2-ones
FI90869C (fi)	1986-11-14	1994-04-11	Tanabe Seiyaku Co	Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
US5164403A (en) *	1991-04-05	1992-11-17	G. D. Searle & Co.	N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
WO1996036616A1 (en)	1995-05-17	1996-11-21	E.I. Du Pont De Nemours And Company	Fungicidal cyclic amides
DE19732928C2 (de) *	1997-07-31	2000-05-18	Gruenenthal Gmbh	Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
ATE257703T1 (de) *	1997-10-27	2004-01-15	Takeda Chemical Industries Ltd	1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
CA2381215A1 (en)	1999-08-06	2001-02-15	Takeda Chemical Industries, Ltd.	P38map kinase inhibitors
EP2172560A3 (en)	2000-02-24	2010-09-29	Xenon Pharmaceuticals Inc.	stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
WO2001074811A2 (en)	2000-03-30	2001-10-11	Takeda Chemical Industries, Ltd.	Substituted 1,3-thiazole compounds, their production and use
JP2002302488A (ja) *	2000-03-30	2002-10-18	Takeda Chem Ind Ltd	置換１，３−チアゾール化合物、その製造法および用途
EP1354603A1 (en)	2000-12-26	2003-10-22	Takeda Chemical Industries, Ltd.	Concomitant drugs
US6759554B2 (en)	2001-04-24	2004-07-06	Massachusetts Institute Of Technology	Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
WO2002100433A1 (en)	2001-06-11	2002-12-19	Takeda Chemical Industries, Ltd.	Medicinal compositions
US6706739B2 (en) *	2001-08-21	2004-03-16	National Health Research Institute	Imidazolidinone compounds
AU2003256755A1 (en) *	2002-07-24	2004-02-09	Ptc Therapeutics, Inc.	Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
SE0301232D0 (sv) *	2003-04-25	2003-04-25	Astrazeneca Ab	Novel use
WO2005077937A1 (en)	2004-01-09	2005-08-25	Cadila Healthcare Limited	Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (en)	2004-07-27	2006-02-01	Aventis Pharma S.A.	Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7767677B2 (en) *	2004-09-20	2010-08-03	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
DE602007010287D1 (de)	2006-06-05	2010-12-16	Novartis Ag	Organische verbindungen
KR20090040385A (ko) *	2006-08-15	2009-04-23	노파르티스 아게	증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물
JP2010501567A (ja)	2006-08-24	2010-01-21	ノバルティスアクチエンゲゼルシャフト	代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
JP5351025B2 (ja)	2006-09-22	2013-11-27	ノバルティスアーゲー	ヘテロ環式有機化合物
EA200900820A1 (ru)	2006-12-20	2010-02-26	Новартис Аг	2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд)
EA022797B1 (ru)	2008-02-20	2016-03-31	Новартис Аг	ТРИАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ СТЕАРОИЛ-CoA-ДЕСАТУРАЗЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ, И ИХ ПРИМЕНЕНИЕ
EP2307379A2 (en)	2008-06-27	2011-04-13	Novartis AG	Organic compounds

2007
- 2007-08-13 KR KR1020097005250A patent/KR20090040385A/ko not_active Application Discontinuation
- 2007-08-13 EP EP07873509.9A patent/EP2054408B1/en active Active
- 2007-08-13 MX MX2009001634A patent/MX2009001634A/es active IP Right Grant
- 2007-08-13 US US12/377,499 patent/US8063084B2/en not_active Expired - Fee Related
- 2007-08-13 KR KR1020117011700A patent/KR20110077006A/ko not_active Application Discontinuation
- 2007-08-13 UA UAA200900859A patent/UA96766C2/ru unknown
- 2007-08-13 MY MYPI20090434A patent/MY153263A/en unknown
- 2007-08-13 CA CA2660201A patent/CA2660201C/en not_active Expired - Fee Related
- 2007-08-13 NZ NZ574222A patent/NZ574222A/en not_active IP Right Cessation
- 2007-08-13 TW TW096129875A patent/TWI404718B/zh not_active IP Right Cessation
- 2007-08-13 PE PE2007001082A patent/PE20081316A1/es not_active Application Discontinuation
- 2007-08-13 WO PCT/US2007/075802 patent/WO2008127349A2/en active Application Filing
- 2007-08-13 KR KR1020127026540A patent/KR20130036080A/ko active Application Filing
- 2007-08-13 BR BRPI0716407-6A patent/BRPI0716407A2/pt not_active IP Right Cessation
- 2007-08-13 JP JP2009524754A patent/JP4972690B2/ja not_active Expired - Fee Related
- 2007-08-13 ES ES07873509.9T patent/ES2597453T3/es active Active
- 2007-08-13 KR KR1020147001838A patent/KR20140019873A/ko not_active Application Discontinuation
- 2007-08-13 CN CN2007800303661A patent/CN101535303B/zh not_active Expired - Fee Related
- 2007-08-13 RU RU2009109147/04A patent/RU2009109147A/ru unknown
- 2007-08-13 CL CL200702348A patent/CL2007002348A1/es unknown
- 2007-08-13 PE PE2011000441A patent/PE20110371A1/es not_active Application Discontinuation
- 2007-08-13 AU AU2007351498A patent/AU2007351498B2/en not_active Ceased
- 2007-08-13 PE PE2011000443A patent/PE20110341A1/es not_active Application Discontinuation
- 2007-08-13 AR ARP070103586A patent/AR062360A1/es unknown
- 2007-08-13 NZ NZ598548A patent/NZ598548A/xx not_active IP Right Cessation
2009
- 2009-01-13 ZA ZA2009/00263A patent/ZA200900263B/en unknown
- 2009-01-15 IL IL196562A patent/IL196562A0/en unknown
- 2009-01-16 CR CR10566A patent/CR10566A/es not_active Application Discontinuation
- 2009-02-06 GT GT200900027A patent/GT200900027A/es unknown
- 2009-02-13 CO CO09014467A patent/CO6241156A2/es active IP Right Grant
- 2009-02-13 TN TN2009000045A patent/TN2009000045A1/fr unknown
- 2009-02-20 MA MA31653A patent/MA30655B1/fr unknown
- 2009-03-11 NO NO20091083A patent/NO20091083L/no not_active Application Discontinuation
2011
- 2011-09-13 US US13/231,075 patent/US8293768B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NZ574222A (en)	2012-03-30
RU2009109147A (ru)	2010-09-27
EP2054408B1 (en)	2016-07-13
PE20110371A1 (es)	2011-06-24
NZ598548A (en)	2013-09-27
KR20110077006A (ko)	2011-07-06
US8063084B2 (en)	2011-11-22
TW200815427A (en)	2008-04-01
JP4972690B2 (ja)	2012-07-11
US8293768B2 (en)	2012-10-23
BRPI0716407A2 (pt)	2014-05-20
AR062360A1 (es)	2008-11-05
AU2007351498B2 (en)	2012-04-05
WO2008127349A3 (en)	2009-02-12
CO6241156A2 (es)	2011-01-20
CN101535303A (zh)	2009-09-16
IL196562A0 (en)	2009-11-18
JP2010501488A (ja)	2010-01-21
KR20090040385A (ko)	2009-04-23
ES2597453T3 (es)	2017-01-18
NO20091083L (no)	2009-04-28
KR20140019873A (ko)	2014-02-17
MA30655B1 (fr)	2009-08-03
MX2009001634A (es)	2009-02-25
PE20110341A1 (es)	2011-06-21
EP2054408A2 (en)	2009-05-06
GT200900027A (es)	2010-06-01
KR20130036080A (ko)	2013-04-09
TWI404718B (zh)	2013-08-11
AU2007351498A1 (en)	2008-10-23
CL2007002348A1 (es)	2008-08-08
ZA200900263B (en)	2011-11-30
UA96766C2 (ru)	2011-12-12
PE20081316A1 (es)	2008-10-16
US20120004164A1 (en)	2012-01-05
US20100233116A1 (en)	2010-09-16
CA2660201C (en)	2016-05-03
CR10566A (es)	2009-03-11
TN2009000045A1 (en)	2010-08-19
WO2008127349A2 (en)	2008-10-23
CN101535303B (zh)	2012-07-18
CA2660201A1 (en)	2008-10-23

Publication	Publication Date	Title
MY153263A (en)	2015-01-29	Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
JO3014B1 (ar)	2016-09-05	مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة
WO2009156484A3 (en)	2010-05-14	Organic compounds
MX2009006728A (es)	2009-09-09	Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
WO2007143597A3 (en)	2008-04-10	Organic compounds
MX2009006706A (es)	2009-07-02	Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
SG161318A1 (en)	2010-05-27	Heterocyclic inhibitors of mek and methods of use thereof
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TN2010000203A1 (en)	2011-11-11	Beta-lactamase inhibitors
PL1979355T3 (pl)	2011-04-29	Pochodne spiro imidazoli jako modulatory PPAR
TW200740803A (en)	2007-11-01	Heterocyclic derivatives as modulators of ion channels
TW200716546A (en)	2007-05-01	Oxindole compounds and their uses as therapeutic agents
TW200724543A (en)	2007-07-01	Heterocyclic compounds and their uses as therapeutic agents
HK1131971A1 (en)	2010-02-12	Benzimidazole modulators of vr1 vr1
MX2009006339A (es)	2009-08-21	Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TNSN08373A1 (en)	2009-12-29	Azolopyrimidines as inhibitors of cannabinoid 1 activity
MX2009007337A (es)	2009-07-15	Indazoles sustituidos con 5-piridinona.
EA201000895A1 (ru)	2010-12-30	Композиции и способы для лечения лизосомных болезней
ZA201003352B (en)	2011-08-31	Heterocyclic derivatives as modulators of ion channels
TN2012000085A1 (en)	2013-09-19	Pyrazole derivatives which modulate stearoyl-coa desaturase
WO2007081808A3 (en)	2008-04-03	Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
TN2010000378A1 (en)	2011-12-29	Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000598A1 (en)	2012-05-24	Organic compounds